Since the FDA announced that tirzepatide is (for now) out of shortage, APC’s Scott Brunner has been all over the news offering our perspective. Here’s just a sampling:
Axios: “FDA warns compounding pharmacies on weight-loss drugs“
Fierce Pharma: “Eli Lilly’s shortage of diabetes and obesity drugs is over, halting competition with knock-offs“
The New York Times: “Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says“
The Washington Post: “Eli Lilly’s weight-loss drug no longer in shortage, FDA says“